郭宏伟;杨文秀;孟青;
GUO Hongwei,YANG Wenxiu,MENG Qing(Department of Pathology,Guiyang Medical College,Guiyang 550004,Guizhou,China)

• 1:贵阳医学院附院病理科
• 2:贵阳医学院附院病理科
• 3:贵阳医学院附院病理科 贵州贵阳550004 贵阳医学院病理学教研室2006级硕士研究生
• 4:贵州贵阳550004

摘要(Abstract)：

目的:观察胃肠B细胞性非霍奇金淋巴瘤的临床病理特征,Bcl-2、ki-67、CD5的表达和幽门螺杆菌(Hp)的感染对其临床病理特征及预后的影响。方法:收集18例病人的临床病理资料并进行随访,通过HE及免疫组织化学染色,观察黏膜相关淋巴瘤及氵弥漫大B细胞淋巴瘤的组织学特点,检测Bcl-2、ki-67、CD5及Hp,对所得资料进行统计学分析。结果:CD5、ki-67表达及Hp感染均随着临床分期的增加而增加。Bcl-2阳性组及ki-67表达>30%组的淋巴结累及率要高于Bcl-2阴性组及ki-67表达≤30%组。CD5阳性组的生存状况要好于阴性组,而ki-67表达>30%组及Hp感染组生存状况要差于ki-67表达≤30%组及Hp未感染组。结论:Bcl-2、CD5表达、ki-67高表达及Hp感染可能与晚期淋巴瘤有关,Bcl-2表达、ki-67高表达可能与淋巴结受累有关,而ki-67表达、Hp感染与较差的生存状况相关。
Objective:To observe the clinicopathogical features of gastrointestinal B cell lymphomas,expression of Bcl-2,CD5,Ki-67 and the influence of Helicobacter pylori(Hp) infection to clinicopathogical features and prognosis of patients.Methods:The clinicopathogical data of 18 patients were collected and further follow-up was carried out.The expression of Bcl-2,CD5,Ki-67 and Hp infection were checked by using immunohistochemistry method.All of the data were statistically analyzed.Results:The expression of CD5,and Ki-67,and Hp infection rates increased along with the increasing of the clinical staging of the disease.The rates of lymph node involvement in the groups of Bcl-2-positive and Ki-67 higher(>30%) expression(66.67% and 77.78%) were higher than those in groups of Bcl-2-negative and Ki-67 lower(≤30%) expression(33.33% and 22.22%).The survival rate of CD5-positive group(100%) was higher than that of CD5-negative group(50%),while the survival rates in groups of Ki-67 higher expression and Hp infection-positive(66.67% and 33.33%) were lower than those in groups of Ki-67 lower expression and Hp infection-negative(100% and 83.33%).Conclusion:The advanced stage of the disease seems accompanied by expression of CD5,higher expression of Ki-67 and Hp infection.Lymph node involvement associates with Bcl-2 expression and higher expression of Ki-67.Lower survival rates associate with higher expression of Ki-67 and Hp infection.

关键词(KeyWords)： 淋巴瘤,非霍奇金;淋巴瘤,B细胞;胃肠肿瘤;基因,Bcl-2;ki-67抗原;抗原,CD5;预后
lymphoma,non-Hodgkin;lymphoma,B-cell;gastrointestinal neoplasms;genes,bcl-2;ki-67 antigen;antigens,CD5;prognosis

Abstract:

Keywords:

基金项目(Foundation): 贵州省长基金资助项目(S2004-18);; 贵州省卫生厅科技计划项目(G2005-2)

作者(Author): 郭宏伟;杨文秀;孟青;
GUO Hongwei,YANG Wenxiu,MENG Qing(Department of Pathology,Guiyang Medical College,Guiyang 550004,Guizhou,China)

Email:

DOI: 10.19367/j.cnki.1000-2707.2008.02.005

参考文献(References)：

• [1]Hioka T,Miura I,Kume M,et al.Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma[J].Genes Chromosomes Cancer,2005(2):149-157.
• [2]克晓燕,景红梅.37例黏膜相关淋巴组织型淋巴瘤的病理、临床资料分析[J].北京大学学报,2003(2):123-127.
• [3]Schechter NR,Yahalom J.Low-grade MALT lymphoma of the stomach:A reviewof treatment option[J].Int J Radia-tion Oncol Phys,2000(46):1093-1103.
• [4]Reena Ray,Gao Chen,Christine Vande Velde,et al.BNIP3heterodimerizes with Bcl-2/Bcl-xl and induces cell death independent of Bcl-2homology3(BH3)domain at both mitochondrial and nonmitochondrial sites[J],J Biol Chem,2000(2):1439-1448.
• [5]吕方芳.Urvivin、Bcl-2及ki-67在弥漫大B细胞淋巴瘤中的表达及临床意义[J].肿瘤,2006(10):930-934.
• [6]Yoshioka T,Miura I,Kume M,et al.Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma[J].Genes Chromosomes Cancer,2005(2):149-157.
• [7]Suguro M,Tagawa H,Kagami Y,et al.Expression profi-ling analysis of the CD5+diffuse large B-cell lymphoma subgroup:development of a CD5signature[J].Cancer Sci,2006(9):868-874.
• [8]Nakamura S,Matsumato T.Chromosomal translocation t(11;18)(q21;q21)in gastrointestinal mucosa associated lymphoid tissue lymphoma[J].J Clin Pathol,2003(56):36-42.
• [9]Ye H T,Liu H X,Attygalle A,et al.Variable frequencies of t(11;18)(q21;q21)in MALTlymphoma of differentsites:significant association with CagAstrain of Hpylori in gastric MALT lymphoma[J].Blood,2003(3):1012-1018.
• [10]尹洪芳,李挺.胃肠B细胞淋巴瘤的增殖与调亡及其其与幽门螺杆菌的关系[J].北京大学学报,2004(4):348-352.[11]盛剑秋,李世.胃黏膜相关淋巴样组织瘤与幽门螺杆菌感染的相关性研究[J].中华消化杂志,2002(6):354-356.

文章评论(Comment)：